Indiana is currently home to 1224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients
NCT05874843
Recruiting
The goal of this observational study is to learn about the performance of the TEG6s in normal pediatric patients. The main questions it aims to answer are: What are the normal TEG 6S lab results in normal pediatric patients and how do they compare to existing published reference ranges. Participants and their guardians will be asked to submit a small amount of blood at the beginning of an elective operation for analysis in the TEG 6s machine.
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
05/27/2025
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Coagulopathy
Register for Updates
Ondansetron for the Management of Atrial Fibrillation
NCT05844501
Recruiting
"Afib" is a common irregular heartbeat. Afib can cause stroke, blood clots, dementia and death. Medicines used to treat Afib often do not work well and can cause serious side effects. Clinicians need medicines that work better for Afib. Medicines for Afib work by blocking a current in the heart called a potassium current. There is a newer potassium current called IKas that can contribute to Afib. A medicine called ondansetron is used to keep people with cancer from getting sick to their stomach... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/27/2025
Locations: Indiana Clinical Research Center, Indianapolis, Indiana
Conditions: Atrial Fibrillation
Register for Updates
Maximizing Nutrition Education to Meet Dietary and Food Security of Children and Parents
NCT05196763
Recruiting
Food insecurity and low diet quality are persistent problems linked with chronic disease and poor health among limited-resource children and adults using Supplemental Nutrition Assistance Program (SNAP). We have shown nutrition education via adult-focused, direct SNAP-Education (SNAP-Ed) improved household food security by 25% but not adult dietary quality among SNAP-eligible households using a randomized, controlled, longitudinal SNAP-Ed intervention in Indiana. Households experiencing food ins... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
05/27/2025
Locations: Heather Eicher-Miller, West Lafayette, Indiana
Conditions: Nutrition, Healthy, Hunger, Diet, Healthy, Food Habits
Register for Updates
Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne
NCT04582383
Recruiting
Acne is common illness of adolescents and young adults which is associated with substantial morbidity. While topical treatments are often sufficient for mild acne, moderate to severe acne often requires treatment with systemic medications such as oral antibiotics, hormonal therapies such spironolactone, and isotretinoin. Sebum overproduction is fundamental to the pathogenesis of acne with associated disordered keratinization and subsequent microbial colonization and inflammation resulting in the... Read More
Gender:
FEMALE
Ages:
Between 16 years and 40 years
Trial Updated:
05/27/2025
Locations: Dawes Fretzin Clinical Research Group, Indianapolis, Indiana
Conditions: Acne
Register for Updates
A Study Assessing KB801 for the Treatment of Stage 2 or 3 Neurotrophic Keratitis
NCT06999733
Recruiting
The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via topical application. This is a Phase 1/2, multicenter, double-masked, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of KB801 in these subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Midwest Cornea Associates, Carmel, Indiana
Conditions: Neurotrophic Keratitis
Register for Updates
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
NCT06427395
Recruiting
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Zydus US001, Indianapolis, Indiana
Conditions: Primary Biliary Cholangitis
Register for Updates
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Northwest Cancer Centers, Dyer, Indiana
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
NCT05465174
Recruiting
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/22/2025
Locations: Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana
Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Register for Updates
GammaTile and Stupp in Newly Diagnosed GBM
NCT05342883
Recruiting
In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival. As discussed above it seems unlikely that patient outcomes will be significantly improved with radiation dose escalation given at the time of the EBRT boost. However, as most failures are local, improving LC could potentially improve the OS of patients. To do this, we propose a shift in the traditional radiation paradigm.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Indiana University Office of Clinical Research, Indianapolis, Indiana
Conditions: Glioblastoma
Register for Updates
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
NCT06433635
Recruiting
This is a sequential multiple assignment randomized trial for adults (ages \> 18) with a bipolar disorder type 1 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar depression, which includes three FDA-approved medications (Cariprazine, Quetiapine and Lurasidone) and one antipsychotic/antidepressant combination (Aripiprazole/Escitalopram).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Steve Strakowski, Bloomington, Indiana
Conditions: Bipolar I Disorder, Depression
Register for Updates
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
NCT02984761
Recruiting
Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana
Conditions: Lung Neoplasm
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/21/2025
Locations: Riley Hospital for Children - Indiana University, Indianapolis, Indiana
Conditions: Langerhans Cell Histiocytosis
Register for Updates